[Medical Newspaper] October 18, 2018
Shin Hyun-soon, CEO, revealed in a shareholder letter that he has “5 technology patents and 9 patent applications, on par with the world’s best.”
Stem cell specialist Miracell (CEO Shin Hyun-soon) announced in a shareholder letter on the 18th that it will dedicate itself to continuous research and development toward becoming the world’s leading stem cell specialist.
Miracell collaborates with domestic and international medical institutions on research and development to specialize in safe stem cell treatments. Miracell aims to lead the way in advanced medical technology, not only treating diseases but also emphasizing ethics and morality. Its goal is to contribute to the development of hospitals and the promotion of public health. CEO Shin Hyun-soon stated, “We are pleased to announce that the Ministry of Food and Drug Safety has approved the manufacture and sale of medical devices, a long-awaited project that has been in the works for a long time. With five registered technology patents and nine pending patents, our technology stands shoulder to shoulder with the world’s best.”
He added, “We are currently conducting a cell count to verify the excellence of our medical devices. We will continue to strive to expand beyond the domestic market and into global export markets, thereby increasing sales and achieving further growth for Miracell.”
Miracell currently holds five technology patents, including a decanting kit for easy ingredient-specific extraction, a centrifuge vessel for easy ingredient-specific extraction, a swing rotor assembly for centrifuges, a centrifuge vessel, and a dual-wavelength laser device for skin treatment.
Furthermore, Miracell holds eight domestic patents and one international PCT patent application, including a centrifuge vessel for easy ingredient-specific extraction, a centrifuge kit for easy sample collection and ingredient separation, a bucket for centrifuges, a component separation plotter for centrifuges, a vending machine for personalized cosmetics manufacturing using AI, and a centrifuge equipped with a charging device.
Meanwhile, Miracell’s stem cell therapy for diabetic lower extremity ischemia and stem cell therapy for knee arthritis were selected as limited new medical technologies and eligible for new support from the Health and Medical Technology Research and Development Project. Professor Chae Dong-sik (Orthopedic Surgery) at International St. Mary’s Hospital has demonstrated a cartilage regeneration rate of over 70% using autologous bone marrow stem cell transplantation using Miracell’s new medical technology, the “Smart Prep 2 Bi-Mac System.” Professor Park Eun-soo (Plastic Surgery) at Soonchunhyang University Bucheon Hospital is also providing hope to patients who previously had to undergo limb amputation through autologous bone marrow stem cell therapy for diabetic lower extremity ischemia.
Reporter Oh In-gyu 529@bosa.co.kr